This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides funding to The Johns Hopkins University to investigate the pathogenesis of immune checkpoint inhibitor-induced myocarditis. The $547,945 award, with a project period from January 1, 2025 to December 31, 2029, supports research aims focused on understanding how biological factors like previous cardiac injury, age, and sex impact the risk of this rare but potentially fatal immune-related adverse event associated with cancer immunotherapies. The researchers will comprehensively characterize the 3D localization and transcriptional profile of autoreactive, tissue-resident memory T cells specific to cardiac myosin, and assess if depleting these cells can prevent the development of immune checkpoint inhibitor-induced myocarditis in a mouse model. This work aims to aid the development of new targeted therapies for this serious complication of cancer immunotherapies.